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Synopsis 
The thesis entitled “Computer Aided Drug Design Strategies to Model Choline Kinase, 
Phosphodiesterases and Phospholipase Inhibitors” is divided into a total of seven chapters. A 
preamble about computer aided drug design, biologically active compounds, small molecule-
macromolecule interactions and importance of these interactions in a disease state is given in 
Chapter 1. A detailed introduction of various drug design approaches has also given in the same 
chapter. Chapter 2 gives the particulars of various computational approaches employed in the 
thesis, and the theory resides in these concepts, which include force fields, structure and analog 
based methods along with various molecular properties, surfaces and channels that are important 
to understand the protein-ligand interactions. An exhaustive study on subtype selectivity of 
phosphodiesterase 4 by analyzing two PDE4 subtypes, PDE4B and PDE4D, and practical 
strategies to design an inhibitor with enhanced subtype selectivity is discussed in Chapter 3. The 
structural requirements for a set of triarylethane analogues as potent PDE4 inhibitors with the 
help of 3D-QSAR and docking studies are analyzed in Chapter 4. The probable reasons for the 
observed selectivity of a set of PDE5 inhibitors over PDE6 enzyme are studied with the aid of 
QSAR and comparative docking studies with PDE5 and PDE6 proteins are given in Chapter 5.  
An account of successful use of structure and analog based approaches for a test case of PLA2 
enzyme is provided in Chapters 6. Finally, Chapter 7 illustrates the significance of choline 
kinase as a potential target for various cancers together with 3DQSAR and docking analysis of 
bis-quinolinium compounds as active choline kinase inhibitors.  
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Chapter 1: Introduction 
Computer aided drug design (CADD) has emerged as an important topic of academic and 
industrial significance. Discovering and developing any new medicine is a long and expensive 
process. A new compound must not only produce the desired response with minimal side effects 
but must also be demonstrably better than the existing therapies. Two key steps in many drug 
discovery programmes are the identification of a lead series (lead identification) and its 
optimization (lead optimization). A historical introduction along with the importance of this filed 
in rational drug design is presented at the beginning of this chapter. The interaction between a 
ligand and its target may be due to entirely non-bonded forces, with few exceptions to take place 
covalent interactions. Drugs can be classified as agonist, antagonist or inverse agonists. The 
details of different ways how the above three classes will interact with their respective targets to 
produce their action continued the chapter to next topics. The following topic of the chapter is a 
comprehensive description of drug design cycle with a special focus on analog and structure 
based approaches. 
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Chapter 2: Methodology 
 Ligand and protein preparation is an important and critical step in setting up 
computational methods aimed at understanding drug-receptor interactions. Assigning appropriate 
atom types, correct protonation state, chirality and conformation are necessary to model any 
biologically active compound which includes small as well as macromolecules. In this regard 
proper selection of a force field, which is suitable to a particular molecule, is very important. 
Various molecular mechanics force fields namely, Tripos, MMFF94, and OPLS are available but 
every force field has its own limitation in treating the ligand and protein molecules. Besides 
force field, deciphering the correct conformation of a ligand is very crucial particularly for 3D-
QSAR studies. The details of different components of the force field, method limitations and also 
what force field has to be used to which compound have been employed as a first part of the 
chapter while, the second part discuss mostly about the receptor-inhibitor interactions. A brief 
theoretical background of structure and analog based approaches are given. Active site analysis 
can be performed using techniques like van der Waals, Lee-Richards and Connolly surface 
calculations, which are explained. Similarly, calculation of active site clefts, pockets, surfaces 
and ligand entry channels is explained. Computing different properties namely liphophilic, 
electrostatic, cavity depth, flexibility etc on these surfaces to better understand the nature of the 
active site is also described.  
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Chapter 3: Subtype selectivity of phosphodiesterase 4 (PDE4): A bottleneck in rational drug 
design 
Subtype selectivity of phosphodiesterase 4 (PDE4) has been proposed to be the most 
salient feature for the development of drugs for asthma and inflammation. Structural requirement 
for PDE4 subtype selectivity is analyzed by comparative analysis of existing PDE4B and 4D 
crystal structures. Usually, the lack of a 3-dimensional structure of a target protein is a bottleneck 
for rational drug design approaches. However, in this case the availability of 39 X-ray structures 
along with co-crystals has not improved the therapeutic ratio of drugs through rational drug 
design approaches. The investigation of structures led to find significant variations in the M-loop 
region, which is the integral part of the active site of PDE4B and PDE4D. These differences can 
be accounted for by varying conformation of the Pro430 residue and a Thr436/Asn362 mutation in 
the M-loop that causes variations in adjacent residue properties and also the pattern of hydrogen-
bonding interactions (Figure 1A). The impact of M-loop on inhibitor binding is further 
scrutinized by molcad surfaces and hydrophobicity from which the more hydrophobic nature of 
4B over 4D in the M-loop region is found out (Figure 1B). Generation of molcad channels 
reveals the unexploited pocket in the M-loop region for both 4B and 4D where differences in 
hydrophobicity values were found (Figure 1C). Based on these observations the important 
structural clues to design or to modify the inhibitor structure have been proposed.  
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Figure 1A: The protein tertiary structure is represented in green color helices and purple color 
loops. The secondary structure variation in M-loop region is displayed in red color helix. The 
mutated residues are shown in pink (4B) and blue (4D) color ball and stick. The yellow color 
stick model represents the ligand cAMP and orange color balls the metal atoms Zn and Mg. B) 
Fast Connolly channel is generated for both 4B (green) and 4D (yellow). The channel that is 
located in the M-loop is highlighted in red color dotted lines. C) The molcad (fast Connolly) 
surface only for the M-loop region is generated from Sybyl. The surface is colored by 
lipophilicity where brown to blue represents hydrophobic to hydrophilic. The 4B is hydrophobic 
in nature compared to 4D where the threonine residue is mutated to aspargine in 4D and changes 
the property to hydrophilic.   
A 
B 
C 4D4B 
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Chapter 4: Understanding the Structural Requirements of Triarylethane Analogues towards 
PDE4 Inhibitors: A Molecular Modeling Study 
3D-QSAR (CoMFA) and docking studies have been performed on a series of 44 
triarylethanes (Scheme 1) to determine the structural requirements for PDE4 inhibition. 
Considering the stereochemistry of the data set molecules and the varied types of alignments 
available, a total of seven models are presented. While most models were optimized to yield 
satisfactory r2 and q2 values, the best model was obtained with 29 molecules including all the ‘R’ 
conformation with r2 0.996, q2 0.510 and r2pred 0.744 (Figure 2). A complementary molecular 
docking analysis is carried out considering the 29 stereochemically characterized set of 
molecules. The CoMFA maps and the docking studies were used to understand the structural 
requirements for the PDE4 inhibition. These studies are expected to provide useful insights into 
the roles of various substitution patterns on the triarylethane skeleton and also help to design 
more potent compounds. 
 
 
Figure 2: CoMFA steric (green and yellow) and electrostatic (blue and red) contour maps for 
model IV are displayed in the left side figure. Docked conformations of most active (green) and 
least active (atom color) compounds in the active site of PDE4 are shown in the right side 
figure. For comparison, the crystal structure of rolipram is also shown as orange color capped 
stick. 
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Scheme 1: The triarylethane analogues as PDE4 inhibitors considered for the study. The 
experimental activities (IC50 in nM) are given in the parentheses.  
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Chapter 5: Molecular Modeling Studies of Pyridopurinone Derivatives – Potential 
Phosphodiesterase5 Inhibitors 
Two- and three-dimensional quantitative structure-activity relationship (QSAR) and 
docking studies were carried out on a series of pyridopurinones (Table 1), to model their PDE5 
inhibitory activities. 2D-QSAR was performed using the heuristic and BMLR methods, which 
had given linear models between the inhibitory activity and five descriptors of PDE5 inhibitors, 
with r2-0.987, 0.987, q2-0.970, 0.970, F-166.71, 166.71 and s2-0.0004, 0.0176, respectively 
(Figure 3). 3D-QSAR methods namely CoMFA and CoMSIA had provided statistically 
significant models with q2 values of 0.784, 0.742 and r2 values of 0.975, 0.972 respectively 
(Figure 4). The predictive ability of the models was validated using a set of 6 compounds that 
were not included in the training set and the predictive r2 obtained for the test set was 0.901 and 
0.888 respectively. Docking studies were employed to determine the probable binding 
conformation of these analogues in the PDE5 active site using the programs GOLD and 
AutoDock (Figure 5) whose results were found complementary with 3D-QSAR maps. Since the 
potency towards PDE5 and the selectivity over PDE6 is important for the successful 
development of new PDE5 inhibitors, a comparative docking was performed with PDE6 
homology modeled protein. The probable reasons were investigated for the observed selectivity 
of these molecules towards PDE5 over PDE6. A combined analysis of all the above results 
provides a new insight into the protein-inhibitor interactions and helpful in designing potent and 
selective PDE5 inhibitors for the treatment of erectile dysfunction.   
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Table 1: Dataset of molecules considered for present study. The experimental activities are 
given in pIC50 units. 
N
NH ON
N
R 3 R 4
R 2
R 1
O
N
NH ON
N
R 3 R 4
R 2
R 1
O
O 2S N
N R 5
N
NH ON
O
O 2S N
N
N
231-12 13-22
R 5
 
Compound No. R1 R2 R3 R4 R5 pIC50 
1 CH3 H H H H 5.978 
2 H CH3 H H H 6.071 
3 H H CH3 H H 6.419 
4 H H H CH3 H 6.935 
5 H H Br H H 5.665 
6 H H Br CH3 H 6.148 
7 Br H Br CH3 H 5.677 
8 H H H C2H5 H 6.197 
9 H H CN H H 5.476 
10 H H CN CH3 H 5.312 
11 H H H CH2-N-Pr H 5.876 
12 H H H CH2-N-Pi H 5.804 
13 H H H H CH3 6.056 
14 CH3 H H H CH3 7.096 
15 H CH3 H H CH3 6.950 
16 H H CH3 H CH3 7.318 
17 H H H CH3 CH3 7.886 
18 H H Br H CH3 6.835 
19 H H Br CH3 CH3 7.481 
20 H H H C2H5 CH3 7.420 
21 H H H CH3 C2H5 8.045 
22 H H H CH3 CH(CH3)2 7.823 
23 - - - - - 8.522 
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Figure 3: The predicted vs. experimental activities of training and test sets of PDE5 using 
heuristic and BMLR models are plotted in the graphs. 
 
A B C 
Figure 4A & B: The steric and electrostatic maps resulted from CoMFA and CoMSIA models. 
C: The hydrophobic (orange and white) and hydrogen bond acceptor (cyan and purple) maps 
resulted from CoMSIA model. 
 
 
 
 
 
 
Figure 5: The binding poses of most active 21 (orange), moderate active 14 (green) and least 
active 10 (cyan) inside the active site of PDE5. Important active site residues are shown as 
capped stick model, hydrogen bonds are shown in yellow color lines and important distances are 
shown in dotted lines. The interactions with the water molecule can be seen clearly in the right 
side figure. 
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Chapter 6: 3D-QSAR and Molecular Docking Studies of 1-Arylsulfamido-2-Alkylpiperazine 
Derivatives as a Set of Group I and II Secreted PLA2 Inhibitors 
3D-QSAR approaches (CoMFA and CoMSIA) and docking studies were applied to 26 
analogues of 1-aryl sulfamido-2-alkyl piperazines (Table 2) to model the group I and II secreted 
Phospholipases A2 (sPLA2s) activities. Statistically significant robust models, with good 
correlation coefficients and appreciable predictive abilities, have been built and analyzed. The 
best CoMFA model, where 20 molecules in the training set and 6 in the test set, yields cross-
validated (q2) and conventional correlation coefficients (r2) of 0.703 and 0.962 respectively. The 
CoMSIA model, which comprised of a combination of steric, electrostatic, hydrophobic and 
hydrogen bonding components, yield q2 and r2 values of 0.408 and 0.922 respectively. The 
predictive statistics of CoMFA was evaluated by implementing a test set of six, which resulted in 
quite satisfactory predictive correlation coefficient of 0.795. Further docking analysis has been 
performed, using FlexX and GOLD methodologies taking the X-ray structure of human and 
bovine PLA2s and a comparison is made based on the differences in the binding residues of 
bovine and human PLA2s at the active site. The elegant complementary of the analog (Figure 6) 
and structure (Figure 7) based approaches provide valuable insights into the enzyme-ligand 
interaction at the receptor, which eventually enhances our understanding of the structural 
requirements for the design of novel and potential PLA2 inhibitors. 
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Table 2: Dataset for PLA2 inhibitors considered for the present study. The IC50 values are 
provided in µM units. 
NH2N
+ S
O
O
R2
R1
NH2N
+ S
O
O
R2
R1
NH2N
+ S
O
O
R2
R1
(1-26, 32) (27-29) (30, 31)  
S. No R1 R2 IC50 S. No R1 R2 IC50 
1 nC5H11 p-CH3 100 17 7(Z)nC12H23 p-OCH3 3.80 
2 nC7H15 p-CH3 17.30 18 7(E)nC12H23 p-OCH3 2.30 
3 nC9H19 p-CH3 8.80 19 nC12H25 p-Br 5.40 
4 nC12H25 p-CH3 2.45 20 nC12H25 p-NH2 2.00 
5 nC14H29 p-CH3 9.00 21 nC12H25 p-N(CH3)2 1.40 
6 nC7H15 p-H 19.30 22 nC12H25 p-NHCOCH3 2.20 
7 nC7H15 p-SO2CH3 51.25 23 nC12H25 p-NHCO2Et 2.20 
8 nC7H15 p-Cl 16.70 24 nC12H25 p-NHCOC6H5 2.50 
9 nC7H15 p-OCH3 10.00 25 nC12H25 p-CH(CH3)2 100 
10 nC7H15 o-OCH3 37.70 26 nC12H25 p-CH2CH3 100 
11 nC7H15 m-OCH3 17.00 27 nC9H19 p-CH3 12.10 
12 nC7H15 3,4,5-triOCH3 33.80 28 nC12H25 p-CH3 5.50 
13 nC12H25 p-H 8.00 29 nC14H29 p-CH3 6.80 
14 nC12H25 p-SO2CH3 3.00 30 (R)CH2OC14H29 p-OCH3 2.76 
15 nC12H25 p-Cl 7.50 31 (S)CH2OC14H29 p-OCH3 2.90 
16 nC12H25 p-OCH3 1.90 32 nC16H33 p-CH3 80.00 
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a  b  c 
Figure 6: The resulted CoMFA steric and electrostatic (a), and CoMSIA hydrophobic, donor and 
acceptor (b) contour maps. The different colors represent as follows: green (favored) and yellow 
(disfavored) for steric, blue (electropositive) and red (electronegative) for electrostatic, orange 
(favored) and white (disfavored) for hydrophobic, cyan (favored) and purple (disfavored) for 
donor and magenta (favored) and white (disfavored) for acceptor. 
 
Figure 7: Active site residues are displayed for both bovine (1KV2) and human (1DB4) sPLA2s, 
which are colored green and red respectively. The hydrogen bonds with Gly32 and Tyr69 (of 
bovine) and important interactions with Ca2+ are showed as black color dotted lines. The docked 
conformation of most active compound is displayed in the figure. 
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Chapter 7: Delving the Structural Requirements of Choline Kinase Inhibitors: A Case Study 
of bis-Quinolinium Compounds 
Choline Kinase (ChoK) is reported to involve in cell signaling pathways and cell growth 
by regulating the intermediate, phosphocholine (PCho), which is the first step to biosynthesis a 
membrane phospholipid, phosphatidylcholine. The PCho levels are overexpressed due to 
elevated activation of the protein under carcinogenesis conditions. ChoK has thus evolved as a 
novel target for various cancers and a range of compounds has been reported in this course as 
potent ChoK inhibitors. However, not much information is known about the binding site of the 
inhibitors. Therefore, the possible binding site of 39 bis-quinolinium inhibitors (Table 3) is 
unraveled by successful application of ligand and structure based approaches. Molecular docking 
and 3D-QSAR studies namely CoMFA and CoMSIA were performed on the series (Figure 8). 
The knowledge of the active site was obtained from the Site ID search and molcad surface 
calculations of Sybyl, which was further considered for docking studies. In 3D-QSAR, the best 
predictions were obtained from the model where 30 compounds were considered in the training 
set and remaining 9 in the test set. A comparative analysis was done with the resulted 3D-QSAR 
maps and the docked poses by overlaying the maps on the active site residues. Since, there is no 
reported crystal structure of ChoK with a ligand the present study could provide an idea about 
the binding conformation of the ligand and its interactions with the active site. The results 
possibly will improve our understanding towards the protein active site and what structural 
requirements have needed to be considered while designing the new analogues. 
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Table 3: The series of bis-quinolinium analogs considered in the study and their activities 
N+N
+
LINKER
R4 R4
R3R3
N+N+
LINKER
R4 R4
Cl Cl N+N
+
LINKER
R4 R4
NH2
Me Me
H2N
(1-19) (20-33) (34-39)  
Comp. 
No. Linker R3 R4 IC50 (µM) 
1 
 
H -NH2 1.20 
2 Me -NH2 11.09 
3 H -N(CH3)2 4.40 
4 H perhydroazepinoa 0.50 
5 H anilinob 1.30 
6 H N-methylanilinoc 0.40 
7 H 4-chloro-N-methylanilinod 2.10 
8 
 
H amino 81.10 
9 H dimethylamino 39.70 
10 H perhydroazepinoa 2.20 
11 H anilinob 17.80 
12 H N-methylanilinoc 3.00 
13 H 4-chloro-N-methylanilinod 2.00 
14 
(CH2)2
 
H amino 80.00 
15 H dimethylamino 10.20 
16 H perhydroazepinoa 0.60 
17 H anilinob 2.30 
18 H N-methylanilinoc 1.40 
19 H 4-chloro-N-methylanilinod 4.80 
20 
 
amino 20.60 
21 dimethylamino 9.60 
22 pyrrolidinoe 1.20 
23 N-methylanilinoc 3.10 
24 4-chloro-N-methylanilinod 5.70 
25 
 
amino 63.30 
26 dimethylamino 20.60 
27 pyrrolidinoe 19.80 
28 N-methylanilinoc 11.40 
29 4-chloro-N-methylanilinod 11.40 
30 
(CH2)2
 
dimethylamino 9.00 
31 pyrrolidinoe 1.00 
32 N-methylanilinoc 3.50 
33 4-chloro-N-methylanilinod 5.70 
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34 
 
N-methylanilinoc 56.80 
35 4-chloro-N-methylanilinod 147.00 
36 N-methylanilinoc 96.10 
37 4-chloro-N-methylanilinod 46.10 
38 
(CH2)2
N-methylanilinoc 133.00 
39 4-chloro-N-methylanilinod 57.50 
a- N
 
b- HN
 
c- N
H3C  
d- N
H3C
Cl
 
e- N
 
 
 
 
 
 
 
 
 
 
Figure 8A: CoMFA steric and electrostatic contour maps resulted for the dataset. Green 
indicates bulky group favorable whereas yellow indicates for steric unfavorable region. Blue 
indicates for electropositive charge while red signifies for electronegative charge. B) CoMSIA 
hydrophobic and donor maps resulted for the dataset. The orange and white colors represent 
favorable and unfavorable hydrophobic regions respectively whereas cyan represents for 
hydrogen bond donor regions. C) Docked ligands are displayed in the active site of ChoK. 
Important active site residues are showed as red color ball and stick model. 
A 
B  C 
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